Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9492310.26442/2075-1753_19.10.85-88ArticlesСтатьиResearch ArticleStatins and the liver: a point of view from the cardiologistСтатины и печень: взгляд кардиологаOstroumovaO. DОстроумоваОльга Дмитриевна

д-р мед. наук, проф. каф. факультетской терапии и профболезней; проф. каф. клинической фармакологии и пропедевтики внутренних болезней

ostroumova.olga@mail.ruФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава РоссииФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России151020171910VOL 19, NO10 (2017)ТОМ 19, №10 (2017)858828122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94923

The article is devoted to the safety of statins in terms of hepatotoxicity. These recommendations are presented in terms of monitoring liver function in patients receiving statins. The choice of the optimal scheme of statin therapy from the perspective of the efficiency/safety ratio are discussed.

Статья посвящена безопасности статинов с точки зрения гепатотоксичности. Представлены данные рекомендаций в плане мониторирования функции печени у пациентов, получающих статины. Обсуждаются вопросы выбора оптимальной схемы лечения статинами с позиции соотношения эффективность/безопасность.

statinHMGCoA reductase inhibitorrosuvastatinefficacysafetyadverse effectshepatotoxicitypharmacokineticsстатиныингибиторы редуктазы гидроксиметил-глютарового кофермента Арозувастатинэффективностьбезопасностьпобочные эффектыгепатотоксичностьфармакокинетикаCatapano A.L, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (39): 2999-3058.Catapano A.L, Graham I, De Backer G et al. Рекомендации EOK/EOA по диагностике и лечению дислипидемий 2016. Рабочая группа Европейского общества кардиологов (EOK) и Европейского общества атеросклероза (EOA) по диагностике и лечению дислипидемий. При участии: Европейской ассоциации профилактики сердечно-сосудистых заболеваний и реабилитации (EACPR). Рос. кардиологич. журн. 2017; 5 (145): 7-77.Кукес В.Г. и др. Клиническая фармакология. Учебник. Под ред. В.Г.Кукеса, Д.А.Сычева. М.: ГЭОТАР-Медиа, 2015.Law M, Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A): 52C-60C.Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a studylevel network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390-9.Силивончик H.H. Статины и печень: безопасность. Мед. новости. 2011; 8: 24-30.Silva M.A, Swanson A.C, Gandhi P.J, Tataronis G.R. Statin-related adverse events: a metaanalysis. Clin Ther 2006; 28 (1): 26-35.Marcum Z.A, Vande Griend J.P, Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264-71.Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-5.Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12.Кухарчук B.B. Гиполипидемические препараты. Глава 17 в справочнике по медикаментозному лечению сердечно-сосудистых заболеваний. Под ред. Е.И.Чазова. М.: Практика, 2015; с. 261-2.Katsiki N, Athyros V.G, Karagiannis A, Mikhailidis D.P. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.Lioudaki E, Ganotakis E.S, Mikhailidis D.P. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-43.Korantzopoulos P, Tzimas P, Kalantzi K et al. Association between serum gamma-gluta- myltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582-9.Yun K.E, Shin C.Y, Yoon Y.S, Park H.S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533-7.Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl. 1): S40-3.Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177-93.McKenney J.M, Jones P.H, Adamczyk M.A. et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689-98.Wlodarczyk J, Sullivan D, Smith M. Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. Am J Cardiol 2008; 102: 1654-62.Everett B.M, Mora S, Glynn R.J. et al. Safety Profile of Subjects Treated to Very Low Low- Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682-9.FellstrDm B.C, Jardine A.G, Schmieder R.E. et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-407.Kjekshus J, Apetrei E, Barrios V. et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.Tavazzi L, Tognoni G, Franzosi M. et al. on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635-41.GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-30.Brewer H.B. Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K-29K.Bays H, Cohen D.E, Chalasani N, Harrison S.A. An Assessment by the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidology 2014; 8: S47-S57.Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-4.Nakahara T, Hyogo H, Kimura Y. et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2012; 42: 1065-72.Напалков Д.А. Безопасность статинов: что нужно знать практикующему врачу? Рациональная фармакотерапия в кардиологии. 2014; 10 (3): 331-5.